INTRODUCTION
============

Operators sometimes perform minimally invasive spine surgery (MISS) while ignoring the primary concerns of their patients including anxiety and pain during the perioperative period. There is considerable difference of opinion between the two groups. From the operators\' perspective, the MISS is considered to be less invasive and less painful compared with conventional surgery. Therefore, they confidently choose local anesthesia along with conscious sedation (CS) or monitored anesthetic care (MAC) for the MISS. In contrast, patients have suffered through a considerable period of intractable spinal pain before the operation and expect the procedure to completely alleviate this pain. Patients believe the procedure of MISS will provoke no pain or endurable pain due to their doctors\' explanation of the procedure and its inherent minimal damage to the normal structures.

It is difficult to find a combination of intravenous drugs for CS or MAC to guarantee no respiratory depression without intubation during MISS in a prone position. Due to delaying the procedure and an increased risk of infection while performing MISS, it is difficult to halt the procedure and rotate the patient from the prone position to the supine position in order to secure the airway. In addition, recognition of nerve damage during the MISS must be ensured. Therefore, patients are given insufficient analgesia and sedation while enduring intolerable anxiety and pain. The doctor-patient relationship may be broken even after a successful MISS due to the patient\'s painful experience. Patients who have suffered from intolerable anxiety and pain are unlikely to recommend the MISS to their colleagues or other potential patients.

Dexmedetomidine, an imidazoline compound, is a highly selective α~2~-adrenoceptor agonist with sedative, amnestic, sympatholytic, and analgesic properties. Its great merit is providing a passage from a cooperative conscious sedation to an uncooperative, unconscious hypnosis while securing the ability of self-reporting the risk of upcoming potential nerve damage and insuring spontaneous respiration. These merits of dexmedetomidine will provide an ideal anesthetic condition regardless of adverse effects such as hypotension/bradycardia intraoperatively and delayed emergence postoperatively.

The brief history of the drug, the mechanisms of amnesia/sedation, analgesia, and sympatholysis, the pharmacokinetics and pharmacodynamics, and the clinical application, especially for a procedural sedation during percutaneous endoscopic lumbar discectomy (PELD) - a representative MISS - will be focused on in this paper.

BRIEF HISTORY
=============

Medetomidine (Domitor®, Orion Corporation, Espoo, Finland) was launched as an animal sedative in 1987. Dexmedetomidine (Precedex®, Abbott Laboratories, North Chicago, IL), the S-enantiomer of medetomidine, received approval from the Food and Drug Administration (FDA) in 1999, and was indicated for sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting for up to 24 hours.

An additional FDA-approved indication of this drug in 2008 was sedation of non-intubated patients prior to and/or during surgical and other procedures. This 200 µg of 2 ml dexmedetomidine must be diluted in 0.9% sodium chloride solution prior to administration.

The premixed ready-to-use preparation (Precedex® Premix, Hospira Inc, Lake Forest, IL) is available in 50 and 100 ml sizes since 2012.

Various α~2~ adrenoreceptor ligands are now available. In the chemical class of imidazoline: oxymetazoline, brimonidine for ocular hypertension and clonidine for hypertension and pain, as well as dexmedetomidine. In the chemical class of guanidine: guanfacine and guanabenz for hypertension have been developed \[[@B1]\].

MECHANISMS OF ACTION
====================

Dexmedetomidine, an imidazoline compound, is a highly selective α~2~-adrenoceptor agonist with sedative, amnestic, sympatholytic, and analgesic properties. It has 8 times more selectivity for α~2~ receptors than clonidine (clonidine selectivity: α~2~ : α~1~ = 200 : 1; dexmedetomidine selectivity: α2 : α1 = 1,620 : 1), especially for the 2~A~ subtype. On the other hand, it also has twice as much selectivity for imidazoline receptors than clonidine (clonidine selectivity: α~2~ : imidazoline = 15 : 1; dexmedetomidine selectivity: α~2~ : imidazoline = 30 : 1), especially for type 1 \[[@B2],[@B3]\].

Adrenoceptors are found in nearly all peripheral tissues and in many neuronal populations within the central nervous system. Both norepinephrine and epinephrine play important roles in the control of blood pressure, myocardial contractile rate and force, airway reactivity, and a variety of metabolic functions. Adrenoceptor activation in the locus coeruleus (LC) has direct and indirect effects on the activity of many other neuronal nuclei within the brain \[[@B4]\].

Adrenoceptors can be classified into α~1~ (α~1A~, α~1B~, and α~1D~), α~2~ (α~2A~, α~2B~, and α~2C~), β~1~, β~2~, and β~3~ subtypes. Multiple subtypes often coexist in a particular tissue or even on an individual cell. They can mediate opposing (i.e., α~2~ versus β), redundant (i.e., β~1~ and β~2~), or synergistic responses (i.e., α~1~ and β~2~). According to adrenergic receptors, they have their own preferred linkages to G-protein families and effectors ([Table 1](#T1){ref-type="table"}) \[[@B5]\]. Dexmedetomidine blocks presynaptic α~2~ receptors as a negative feedback system resulting in suppression of norepinephrine (NE) release \[[@B6]\].

1. Action mechanisms of sedation and hypnosis
---------------------------------------------

The sedative/hypnotic response to dexmedetomidine is mediated in the LC in the dorsal wall of the rostral pons, located in the lateral floor of the fourth ventricle. The LC is known as the site of the largest noradrenergic cell body aggregate of the brain, including a high density of α~2~-adrenergic receptors. Wakefulness or vigilance is associated with an increase in the firing rate of the LC \[[@B7]\]. Agonist activation of α~2~-adrenergic receptors in the LC suppresses the firing of the noradrenergic neurons, resulting in hypotension, bradycardia, and sedation/hypnosis \[[@B8]\]. The sedation/hypnosis induced by dexmedetomidine mimics normal physiologic sleep in its cardiovascular and respiratory effects, and involves an endogenous sleep-promoting pathway \[[@B8],[@B9]\].

The normal endogenous sleep-promoting pathway, which converts from a wakeful state to a non-rapid eye movement (NREM) state, is found in the pons, midbrain, hypothalamus, and cortex. The main arousal-sleep pathway begins with an inhibition of noradrenergic neurons in the LC in the pons releases a tonic noradrenergic inhibition of the ventrolateral preoptic nucleus (VLPO) in the anterior hypothalamus. The activated VLPO releases γ-aminobutyric acid (GABA) and galanin (GAL) into the tuberomammillary nucleus (TMN) in the posterior hypothalamus. The TMN, as representative of arousal centers, inhibits its release of arousal-promoting histamine into the cortex (PFA, and VLPO), and thus induces loss of consciousness.

Other arousal-promoting neurotransmitters and their pathways to the cortex are: 1) serotonin (5-hydroxytryptamine, 5-HT) from the dorsal raphe nucleus (DRN) in the pons; 2) orexin (ORX, hypocretins) from the perifornical area (PFA) in the lateral hypothalamus; 3) NE from the LC in the pons, and 4) acetylcholine (ACh) from the laterodorsal tegmental nuclei (LDTN) and pedunculopontine tegmental nuclei (PPTN).

Therefore, if the arousal-promoting neurotransmitters - including histamine, as well as 5-HT, ORX, NE, and Ach - are released from TMN, DRN, PFA, LC, and LDTN/PPTN, respectively, into the cortex, wakefulness is promoted.

When the wakeful state is converted to the NREM sleep state, the most characteristic feature of neurotransmitters in the brain is an increased release of GAL and GABA into the TMN, LC, DRN, PFA, and LDTN/PPTN from the VLPO. And other notable neurotransmitter changes are a decreased release of ORX from the PFA into the TMN and the VLPO and a decreased release of histamine from the TMN into the VLPO and PFA. The release of all 5 arousal-promoting neurotransmitters decreases in the cortex as well.

The answer for why dexmedetomidine shows relatively rapid and complete awake-sleep transitions (one falls asleep and suddenly wakens) might be explained from the flip-flop switch model. The perifornical area in the lateral hypothalamus has ORX neurons which connect TMN and VLPO. Since the VLPO neurons do not have ORX receptors, the ORX neurons serve primarily to reinforce the monoaminergic tone (histamine, NE, and 5-HT), rather than directly inhibiting the VLPO on their own. During wakefulness, the monoaminergic nuclei inhibit the VLPO, thereby relieving the inhibition of the monoaminergic cells, ORX neurons, and Ach neurons. On the other hand, during sleep, the firing of the VLPO neurons inhibits the monoaminergic cell groups. This also allows it to inhibit the ORX neurons, further preventing monoaminergic activation that might interrupt sleep. The direct mutual inhibition between the VLPO and the monoaminergic cell groups forms a classic flip-flop switch, which produces sharp transitions in state, but is relatively unstable. The addition of the orexin neurons stabilizes the switch \[[@B10]\].

Sleep spindles are one of the most important sleep electroencephalogram (EEG) micro-events, originating in the thalamus and then propagating to the cortex. They are considered sleep maintaining events that block the transfer of sensory information to the cerebral cortex during sleep, thus preventing sleep-interrupting arousals. Spindles are short-lasting, oscillatory EEG waveforms with a frequency typically in the high α and low β bands (11-14 Hz) occurring with highest density during S2 sleep and with lower density in deeper S3 and S4 slow-wave sleep. Dexmedetomidine produces a state closely resembling physiological S2 sleep in humans and activates normal non-rapid eye movement sleep (NREM)-promoting pathways \[[@B11]\].

In conclusion, the sedative/hypnotic mechanism of dexmedetomidine-related endogenous sleep pathways involves the inhibition of the LC in the pons, which facilitates VLPO firing in the anterior hypothalamus. The increased release of GABA and GAL at the terminals of the VLPO inhibits TMN firing, which is required for the sedative response in the cortex ([Fig. 1](#F1){ref-type="fig"}) \[[@B8],[@B9]\].

2. Action mechanisms of lack of respiratory depression
------------------------------------------------------

Dexmedetomidine has a biphasic effect on respiratory drive, with low doses decreasing and higher doses increasing resting ventilation in dogs. The locus coeruleus is an important site for the action of α~2~ adrenoceptor agonists. The locus coeruleus is involved in arousal reactions; suppression of its activity by alpha-2 adrenoceptor agonists can result in a state similar to sleep with mild respiratory depression. There is no significant effect on hypercapnic or hypoxic ventilatory drive with α-2 adrenoceptor stimulation \[[@B12]\].

Dexmedetomidine did have some respiratory effects, as would be expected because (1) one of its sites of action is the LC, which is known to play a role in both respiratory control and sleep modulation, and (2) dexmedetomidine converges on the natural sleep pathway to exert its sedative effects, whereas natural sleep results in ventilation modulation. However, the respiratory effects of dexmedetomidine were markedly different from those of opioids or intravenous/inhalative anesthetics. Compared with baseline, during dexmedetomidine infusions, the hypercapnic ventilatory response was unchanged, the respiration rate was significantly increased, and the overall apnea/hypopnea index was significantly decreased. The distribution of ventilatory cycle time/inspiratory time showed an increased peak. More importantly, dexmedetomidine exhibited a hypercapnic arousal phenomenon similar to what has been described during natural sleep \[[@B13]\].

In conclusion, dexmedetomidine shows limited respiratory depression with sedation or hypnosis similar to normal physiologic sleep.

3. Action mechanisms of analgesic property
------------------------------------------

Part of the mechanism by which dexmedetomidine produces an antinociceptive effect is based on action made directly on the LC. Furthermore, the action of dexmedetomidine in the LC in turn may result in an increase in the activation of α~2~ adrenoceptors in the spinal cord \[[@B14]\].

Intrathecal administration of dexmedetomidine alleviates mechanical allodynia induced by chronic constriction injury. Western blotting reveals that dexmedetomidine reduces the activation of microglia and the up-regulation of interleukin-18 protein expression in the ipsilateral lumbar spinal dorsal horn \[[@B15]\].

Systemic α~2~-adrenoceptor stimulation may facilitate inhibitory synaptic responses in the superficial dorsal horn to produce analgesia mediated by activation of the pontospinal noradrenergic inhibitory system \[[@B16]\]. The α~2~ adrenoceptor is highly enriched in spinal dorsal horn and involved in descending noradrenergic pain modification. Action of α~2~-adrenoceptors inhibits N-methyl-D-aspartate (NMDA) receptor-mediated nociceptive transmission in the spinal dorsal horn of mice with inflammatory pain \[[@B17]\].

In conclusion, dexmedetomidine shows an antinociceptive effect by action directly on the LC. It also potentiates descending noradrenergic pain modification and inhibits NMDA receptor-mediated nociceptive transmission in the spinal dorsal horn.

4. Action mechanisms of sympatholysis
-------------------------------------

The activation of presynaptic α~2~-adrenoceptors on sympathetic nerves and in the central nervous system induces sympatholysis, whereas the activation of vascular postsynaptic receptors causes both vasoconstriction (through the activation of α~2~-adrenoceptors on vascular smooth muscle cells) and vasodilatation (through the activation of α~2~-adrenoceptors on endothelial cells).

Alpha2-agonists induce sympatholytic effects through α~2~-adrenoceptors in the central nervous system. Intracerebroventricular administration of dexmedetomidine induces cardiovascular responses mediated by sympathetic inhibition and parasympathetic activation. It also has the potential to decrease blood pressure in a dose-dependent manner because of its α~2~-agonist activity on the sympathetic ganglia and the resulting sympatholytic effects \[[@B18]\].

THE PHARMACOKINETICS AND PHARMACODYNAMICS
=========================================

1. Pharmacokinetics
-------------------

Dexmedetomidine undergoes almost complete biotransformation through direct glucuronidation and cytochrome P450 metabolism (hydroxylation, mediated by CYP2A6), with very little excretion of unchanged molecules in the urine (95%) or feces (4%). It may be necessary to decrease the typical dose in patients with hepatic failure. The elimination half-life is approximately 2 hours. Dexmedetomidine exhibits linear kinetics when infused in the recommended dose range from 0.2 to 0.7 µg/kg/h for no more than 24 hours.

The steady-state volume of distribution is 118 L, and the distribution phase is rapid, with a half-life of distribution of approximately 6 minutes. The average protein binding of dexmedetomidine is 94%, with negligible protein binding displacement by fentanyl, ketorolac, theophylline, digoxin, and lidocaine, all drugs commonly used during anesthesia \[[@B2]\].

There have been no significant sex or age-based differences in the pharmacokinetic profile, even in elderly patients, and pharmacokinetics of the active dexmedetomidine molecule do not change in patients with renal failure. There is, however, a theoretical possibility of accumulation of metabolites of biotransformation because of the high degree of renal clearance of these metabolites \[[@B2]\].

2. Pharmacodynamics
-------------------

Dexmedetomidine is an α-adrenoceptor agonist with dose dependent α~2~-adrenoceptor selectivity. At higher doses (\>1 mg/kg) or in rapid infusions of lower doses, both α~1~- and α~2~-adrenoceptor activities are observed. Patients treated with dexmedetomidine required either no additional sedative medication or only small doses of add-on medications \[[@B2]\].

A biphasic cardiovascular response is observed after application of dexmedetomidine. Initial transient increase of blood pressure and a reflex decrease in heart rate can be explained by the peripheral α~2B~-adrenoceptor stimulation of vascular smooth muscle and can be attenuated by a slow infusion. Both of these effects are caused by the inhibition of the central sympathetic outflow overriding the direct stimulating effects. Another possible explanation for the subsequent decrease of heart rate is the stimulation of the presynaptic α~2~-adrenoceptor, leading to a decreased NE release \[[@B19],[@B20]\].

The application of a single high dose of dexmedetomidine reduces NE and epinephrine releases by as much as 92% in young healthy volunteers. This seems to be more important than either central α~2~-adrenoceptor agonism or non-α adrenaline imidazole-preferring receptors in effecting the change \[[@B21]\].

CLINICAL APPLICATION FOR MISS
=============================

After an additional FDA-approved indication of dexmedetomidine in 2008 for sedation of non-intubated patients prior to and/or during surgical and other procedures, various clinical applications have been introduced \[[@B22],[@B23],[@B24]\].

Most spinal procedures including MISS should be performed in the prone position. Also, most sedative/hypnotic drugs, including midazolam and propofol, never fail to cause respiratory depression. It is difficult to use these drugs on the non-intubated patients who receive MISS procedure in the prone position due to the fatal defect of respiratory depression.

Dexmedetomidine can be used for procedural sedation in the prone position without concern of respiratory depression occurring. Its common adverse effects, bradycardia and hypotension, can be prevented using ketamine. When both dexmedetomidine and ketamine are used together, dexmedetomidine may prevent the tachycardia, hypertension, salivation, and emergence phenomena from ketamine, whereas ketamine may prevent the bradycardia and hypotension, which has been reported with dexmedetomidine. An additional benefit of the added ketamine is an increased speed of sedation, compared with the slow onset time when dexmedetomidine is the sole agent \[[@B25]\]. However, the dose of ketamine over 1 mg/kg in adults may show a range of perceptual distortions, including referential ideas, affective flattening, and alogia, but not hallucination \[[@B26]\].

In case of patients with severe anxiety, a small dose (3-5 mg) of intramuscular injection of midazolam 1 hour before arriving at the operating room can cause antegrade amnesia to rid the patient of unpleasant preoperative memories and anxiety. For the incisional pain, a 5% lidocaine patch is applied to the anticipated working channel site \[[@B27]\]. Intramuscular administration of midazolam compared to intravenous administration has a lower probability of provoking respiratory depression during the operation. A preventive intravenous antibiotic is administrated 30 minutes before operation.

While draping the operation field, continuous intravenous administration of dexmedetomidine mixed with less than 1 mg/kg of ketamine is started. After infusion of 0.4 mg (2 vials, 7 µg/kg) of dexmedetomidine, a favorable skin incisional condition with unconscious sedation is usually accomplished. Fifty µg of fentanyl and 30 mg of ketorolac for analgesia are given in a single dose. It is not recommended to use the more potent ultra-short-acting opioid analgesic, remifentanil, instead of fentanyl, in opioid-naïve patients. It may cause more severe nausea and vomiting during the operation. These adverse effects can delay the progression of the operation by 10 minutes to 1 hour as well as make it necessary to change the position of the patient to maintain an open airway.

Before the anulotome, 50 µg of fentanyl is administered intravenously to relieve the severe intractable pain caused by the anulotome. After the removal of the targeted herniated nucleus pulposus, the infusion of dexmedetomidine should be discontinued to reduce the delayed emergence of the patient.

This delayed emergence from the dexmedetomidine, lasting from 3 to 8 hours, is a major fault of the sedative/hypnotic. This results in an extended fasting period for the patient, similar to that of general anesthesia with a muscle relaxant. It is necessary to prepare an intravenous fluid and electrolyte balance until the patient can eat and drink regularly. Guardians of the patient should be briefed by the operator on the delayed emergence period to reduce anxiety from such a long period without contact between patient and guardian.

Bispectral index (BIS; Aspect Medical Systems Inc., Natick, MA), a monitor of cortical electrical activity, has been used to access the level of sedation/hypnosis for various intravenous or inhalative agents. However, the BIS cannot tell us anything about arousability, and its predictive value is not proven. In physiologic sleep, BIS levels less than 30 were detected, and the volunteers were arousable. This is not the case if propofol and inhalative agents like isoflurane or desflurane are used and these deep levels are achieved. One characteristic of dexmedetomidine seems to be its easy arousability without clinical signs of stress \[[@B28]\]. BIS is not useful for some individual hypnotic agents (ketamine, dexmedetomidine, nitrous oxide, xenon, and opioids) to predict arousability \[[@B29]\].

BIS values at Observer\'s Assessment of Alertness and Sedation (OAA/S) scores of 1, 2, 3, 4, and 5 during dexmedetomidine sedation were noted as 95, 62, 45.5, 39.5, and 24.5, respectively in a previous study. These BIS values showed a different decreasing pattern during the infusion of propofol: 95.5, 78, 67, 57, and 34 from OAA/S score 1 to 5, respectively. The calculated cutoff BIS values for OAA/S scores of ≤ 2 (patient responds only after mild prodding or shaking) were 46 for dexmedetomidine and 67 for propofol \[[@B30]\]. If the BIS value is over 46 after infusion of dexmedetomidine, the patient can respond and report their potential nerve injury during the MISS.

CONCLUSIONS
===========

Dexmedetomidine provides an ideal sedative and hypnotic surgical condition during MISS in a prone position. Additional administration of a small dose of ketamine reassures operators from the worries about respiratory depression with hypotension and bradycardia. It also allows patients to report a potential nerve injury even in a deep sedative and hypnotic state. The greatest drawback is delayed emergence after infusion of high dose of dexmedetomidine.

This study was partially supported by a grant from Pusan National University for a 2-year study between May 2014 and Feb 2016.
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